| Nicholas W Morog, MD | |
|
6518 Meadowridge Rd, Suite 110, Elkridge, MD 21075-6403 | |
| (410) 368-8650 | |
| (410) 368-8655 |
| Full Name | Nicholas W Morog |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 32 Years |
| Location | 6518 Meadowridge Rd, Elkridge, Maryland |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1477512887 | NPI | - | NPPES |
| 0021 | Other | MD | CAREFIRST-DC |
| 520590500 | Medicaid | MD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | D0050812 (Maryland) | Primary |
| 208000000X | Pediatrics | D0050812 (Maryland) | Secondary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Seton Medical Group Inc | 7416037924 | 75 |
News Archive
All the tired ideas from 2011 and 2012 are back: eliminating Medicare's guarantee to retirees by turning it into a voucher plan; dispensing with Medicaid and food stamps by turning them into block grants for states to cut freely; repealing most of the reforms to health care and Wall Street; shrinking beyond recognition the federal role in education, job training, transportation and scientific and medical research.
Esperion Therapeutics, a privately held biopharmaceutical company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced that TransGenRx, a global leader in transgenic technology, will produce protein-based therapeutics to be used in the company's research efforts targeting HDL therapies for the treatment of cardio-metabolic disease.
The London Clinic is one of the first hospitals in the UK to offer prostate artery embolization, a new procedure for non-cancerous enlargement of the prostate, a very common condition in older men.
GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced that two oral presentations and two abstracts were delivered at the 52nd Annual Meeting of the American Society of Hematology in Orlando, Florida. The presentations and abstracts highlighted clinical and preclinical progress with GlycoMimetics's lead compound GMI-1070, now in Phase 2 clinical trials in sickle cell crisis.
The International Contrast Ultrasound Society (ICUS) applauds the announcement of dramatic changes in payment for contrast-enhanced ultrasound (CEUS) imaging of the abdomen.
› Verified 8 days ago
| Entity Name | Seton Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144409194 PECOS PAC ID: 7416037924 Enrollment ID: O20080122000384 |
News Archive
All the tired ideas from 2011 and 2012 are back: eliminating Medicare's guarantee to retirees by turning it into a voucher plan; dispensing with Medicaid and food stamps by turning them into block grants for states to cut freely; repealing most of the reforms to health care and Wall Street; shrinking beyond recognition the federal role in education, job training, transportation and scientific and medical research.
Esperion Therapeutics, a privately held biopharmaceutical company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced that TransGenRx, a global leader in transgenic technology, will produce protein-based therapeutics to be used in the company's research efforts targeting HDL therapies for the treatment of cardio-metabolic disease.
The London Clinic is one of the first hospitals in the UK to offer prostate artery embolization, a new procedure for non-cancerous enlargement of the prostate, a very common condition in older men.
GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced that two oral presentations and two abstracts were delivered at the 52nd Annual Meeting of the American Society of Hematology in Orlando, Florida. The presentations and abstracts highlighted clinical and preclinical progress with GlycoMimetics's lead compound GMI-1070, now in Phase 2 clinical trials in sickle cell crisis.
The International Contrast Ultrasound Society (ICUS) applauds the announcement of dramatic changes in payment for contrast-enhanced ultrasound (CEUS) imaging of the abdomen.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Nicholas W Morog, MD 6518 Meadowridge Rd Ste 110, Elkridge, MD 21075-6458 Ph: (667) 234-8650 | Nicholas W Morog, MD 6518 Meadowridge Rd, Suite 110, Elkridge, MD 21075-6403 Ph: (410) 368-8650 |
News Archive
All the tired ideas from 2011 and 2012 are back: eliminating Medicare's guarantee to retirees by turning it into a voucher plan; dispensing with Medicaid and food stamps by turning them into block grants for states to cut freely; repealing most of the reforms to health care and Wall Street; shrinking beyond recognition the federal role in education, job training, transportation and scientific and medical research.
Esperion Therapeutics, a privately held biopharmaceutical company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced that TransGenRx, a global leader in transgenic technology, will produce protein-based therapeutics to be used in the company's research efforts targeting HDL therapies for the treatment of cardio-metabolic disease.
The London Clinic is one of the first hospitals in the UK to offer prostate artery embolization, a new procedure for non-cancerous enlargement of the prostate, a very common condition in older men.
GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced that two oral presentations and two abstracts were delivered at the 52nd Annual Meeting of the American Society of Hematology in Orlando, Florida. The presentations and abstracts highlighted clinical and preclinical progress with GlycoMimetics's lead compound GMI-1070, now in Phase 2 clinical trials in sickle cell crisis.
The International Contrast Ultrasound Society (ICUS) applauds the announcement of dramatic changes in payment for contrast-enhanced ultrasound (CEUS) imaging of the abdomen.
› Verified 8 days ago
Mark Steven Gosnell, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 6781 Norris Ln, Elkridge, MD 21075 Phone: 410-294-0715 Fax: 410-902-8247 | |
Dr. Joseph F Gibbons, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 8186 Lark Brown Road, Suite 201, Elkridge, MD 21075 Phone: 410-730-3399 Fax: 410-740-4744 | |
Ramesh Kumar, M.D Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 4917 Light Cahill Ct, Elkridge, MD 21075 Phone: 443-986-6259 | |
Steven A. Geller, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 8186 Lark Brown Road, Suite 201, Elkridge, MD 21075 Phone: 410-730-3399 Fax: 410-740-4744 | |
Dr. Sang Wan Kim, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 7305 Brookview Rd Unit 306, Elkridge, MD 21075 Phone: 410-838-0018 Fax: 410-838-0018 | |
Dr. Zhanna Michelle Kalikhman, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 8186 Lark Brown Rd, Suite 301, Elkridge, MD 21075 Phone: 410-730-9898 Fax: 410-730-9990 |